Title
Human Induced Pluripotent Stem Cell-Derived Microglia-Like Cells Harboring TREM2 Missense Mutations Show Specific Deficits in Phagocytosis
Date Issued
28 August 2018
Access level
open access
Resource Type
journal article
Author(s)
Garcia-Reitboeck P.
Phillips A.
Piers T.M.
Butler M.
Mallach A.
Rodrigues C.
Arber C.E.
Heslegrave A.
Zetterberg H.
Neumann H.
Neame S.
Houlden H.
Hardy J.
Pocock J.M.
Publisher(s)
Elsevier B.V.
Abstract
Dysfunction of microglia, the brain's immune cells, is linked to neurodegeneration. Homozygous missense mutations in TREM2 cause Nasu-Hakola disease (NHD), an early-onset dementia. To study the consequences of these TREM2 variants, we generated induced pluripotent stem cell-derived microglia-like cells (iPSC-MGLCs) from patients with NHD caused by homozygous T66M or W50C missense mutations. iPSC-MGLCs expressed microglial markers and secreted higher levels of TREM2 than primary macrophages. TREM2 expression and secretion were reduced in variant lines. LPS-mediated cytokine secretion was comparable between control and TREM2 variant iPSC-MGLCs, whereas survival was markedly reduced in cells harboring missense mutations when compared with controls. Furthermore, TREM2 missense mutations caused a marked impairment in the phagocytosis of apoptotic bodies, but not in Escherichia coli or zymosan substrates. Coupled with changes in apoptotic cell-induced cytokine release and migration, these data identify specific deficits in the ability of iPSC-MGLCs harboring TREM2 missense mutations to respond to specific pathogenic signals. Garcia-Reitboeck et al. describe the generation of human induced pluripotent stem cell-derived microglia-like cells from patients with early-onset dementia caused by variants in the immune receptor gene TREM2. They observed functional deficits in TREM2 variant cells, including reduced soluble TREM2 secretion, selectively reduced phagocytosis of apoptotic neuronal cells, and a deficit in migratory capacity.
Start page
2300
End page
2311
Volume
24
Issue
9
Language
English
OCDE Knowledge area
Inmunología Psiquiatría Neurología clínica
Scopus EID
2-s2.0-85051495052
PubMed ID
Source
Cell Reports
ISSN of the container
22111247
Sponsor(s)
P.G.R. was supported by a clinical research fellowship from Alzheimer’s Research UK . A.P. was supported by a PhD studentship from Complement UK/Alexion (to J.M.P., J.H., and S. Lovestone). T.M.P. and M.B. were scientists at UCL, supported by Eisai , working with the Eisai:UCL Therapeutic Innovation Group (TIG). T.M.P. was also supported by funding to J.M.P. and J.H. from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement 115976 . The Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). C.V.-L. was supported by a studentship from the Peruvian government . C.R. was supported by the Alzheimer's Society , UK. C.E.A. was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre . A.H. was supported by funding from UK Dementia Research Institute, University College London and the Leonard Wolfson Experimental Neurology Centre, University College London . H.Z. is a Wallenberg Academy Fellow . This work was supported by the UK Medical Research Council funding to the MRC Dementia Platform UK ( MR/M02492X/1 ) and Medical Research Council core funding to the High-Content Biology Platform at the Medical Research Council-University College London Laboratory for Molecular Cell Biology university unit ( MC_U12266B ).
Sources of information: Directorio de Producción Científica Scopus